PCAST Working Group, Co-Led by PSMF Founder Joe Kiani, Releases Report on Transforming Patient Safety
8.9.2023 04:43:00 EEST | Business Wire | Press release
The President’s Council of Advisors on Science and Technology (PCAST) released its findings and recommendations on patient safety in a report to U.S. President Joe Biden. Titled “A Transformational Effort on Patient Safety,” the report also outlines the many ways that “patient safety is an urgent national public health issue.” The distinguished PCAST Working Group on Patient Safety is co-led by the founder of the Patient Safety Movement Foundation, Joe Kiani, and Microsoft’s Chief Scientific Officer, Eric Horvitz.
The PCAST report to the Biden-Harris administration pointed out that according to recent data, “Medicare patients suffer an adverse event in one out of four hospitalizations, and one third of those adverse events are serious, including catastrophic outcomes,” and that “adverse outcomes disproportionately impact people from groups historically experiencing social marginalization, widening gaps in healthcare disparities.”
“Preventable medical errors take hundreds of thousands of lives each year. I am optimistic that these recommendations will help fast-track solving this critical problem that destroys so many lives,” said Joe Kiani, co-leader of the PCAST Working Group on Patient Safety. “It was an honor to work with such a distinguished cohort of fellow PCAST committee members on what we believe is an urgent mission, and I am grateful for everyone’s contributions. I know President Biden has been waiting for this report. He is our country’s biggest patient advocate and cares deeply about the very real suffering that happens every day across the U.S. healthcare systems due to medical errors.”
“This is a major milestone in healthcare safety in the United States, and if implemented, we believe it will influence and improve patient safety and healthcare worker safety around the world. Since our inception, we understood that for long-lasting change to happen, it would require direction from the highest levels of government. These recommendations could not have come at a better time because WHO’s World Patient Safety Day is on September 17th,” said Dr. Michael Ramsay, CEO of the Patient Safety Movement Foundation.
The report acknowledges that despite significant efforts made by many healthcare workers and organizations to reduce preventable medical errors by implementing evidence-based safety protocols, nationwide implementation of many of these known solutions has lagged. The report then outlines four recommendations to “advance health equity, improve the nation’s health and well-being, and avert suffering and death for hundreds of thousands of Americans each year.” The recommendations are as follows:
Recommendation 1: Establish and Maintain Federal Leadership for the Improvement of Patient Safety as a National Priority.
1.A Appoint a Patient Safety Coordinator Reporting to the President on Efforts to Transform Patient Safety Among All Relevant Government Agencies.
1.B Establish a Multidisciplinary National Patient Safety Team (NPST) and Ensure Inclusion of Persons from Populations Most Affected.
Recommendation 2: Ensure That Patients Receive Evidence-Based Practices for Preventing Harm and Addressing Risks.
2.A Identify and Address High-Priority Harms and Promote Patient Safety Though Incentivizing the Adoption of Evidence-Based Solutions and Requiring Annual Public Reporting Immediately and Quarterly Public Reporting Within 5 Years.
2.B Create a Learning Ecosystem and Shared Accountability System to Ensure That Evidence-Based Practices are Implemented and Goals for Reduced Harms and Risks of Harm for Every American are Realized.
2.C Advance Interoperability of Healthcare Data and Assure Access to the Tracking of Harms and Use of Evidence-Based Solutions.
2.D Improve Safety for All Healthcare Workers and Their Patients Through Supporting a Just Culture of Patient and Clinician Safety in Healthcare Systems.
Recommendation 3: Partner with Patients and Reduce Disparities in Medical Errors and Adverse Outcomes.
3.A Implement a “Whole of Society Approach” in the Transformational Effort on Patient Safety.
3.B Improve Data and Transparency to Reduce Disparities.
Recommendation 4: Accelerate Research and Deployment of Practices, Technologies, and Exemplar Systems of Safe Care.
4.A Develop a National Patient Safety Research Agenda.
4.B Harness Revolutionary Advances in Information Technologies.
4.C Develop Federal Healthcare Delivery Systems’ Capacities and Showcase Results as Exemplars for Safer Healthcare.
PCAST is a federal advisory committee appointed by the U.S. president to augment the science and technology advice available to him. PCAST consists of 28 of the nation’s thought leaders, selected for their distinguished service and accomplishments in academia, government, and the private sector. Joe Kiani, who founded the Patient Safety Movement Foundation (PSMF) in 2012 and served for many years as its first chair, was appointed to PCAST in September 2021. Also serving with Kiani and Horvitz in the PCAST patient safety working group are:
- Donald Berwick, MD, Patient safety expert, CMS, Institute for Healthcare Improvement
- Lisa Cooper, Johns Hopkins University
- Sue Desmond-Hellmann, Former CEO, Gates Foundation, Former Chancellor UCSF
- Christopher Hart, Safety systems expert, National Transportation Safety Board
- Harlan Krumholz, MD, Outcomes research pioneer, Yale University
- Julie Morath, RN, Patient safety expert, Hospital Quality Institute
- Peter Pronovost, MD, Patient safety expert, University Hospitals Cleveland Medical Center
- Sue Sheridan, Patient advocate, Patients for Patient Safety
ABOUT THE PATIENT SAFETY MOVEMENT FOUNDATION
In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges. The AEBP are available without charge to hospitals online. Hospitals are encouraged to make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms that can identify errors before they become fatal can be developed. The Foundation's annual World Patient Safety, Science & Technology Summit brings together all stakeholders, including patients, healthcare providers, medical technology companies, government employers, and private payers. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare. For more information, please visit psmf.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230907964291/en/
Contact information
Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
